The expression of dystrophin-associated glycoproteins during skeletal muscle degeneration and regeneration. An immunofluorescence study.
The distribution and expression of dystrophin and three of the dystrophin-associated glycoproteins (DAG), alpha-dystroglycan (156 kDa DAG), beta-dystroglycan (43 kDa DAG) and adhalin (50 kDa DAG) in rat skeletal muscle were studied during a controlled cycle of degeneration and regeneration induced by the injection of a snake venom. Cryosections of muscle at various stages of degeneration and regeneration were labeled using monoclonal antibodies to the three glycoproteins and examined at fixed time points after venom injection. Adhalin and alpha-dystroglycan remained present at the sarcolemma throughout the entire cycle of degeneration and regeneration. beta-Dystroglycan, on the other hand, was lost from the sarcolemma by 12 hours and reappeared 2 days after venom injection when new muscle fibers were being formed. Dystrophin was not lost from the sarcolemma until 24 hours after venom injection and did not reappear at the membrane until 4 days. It is suggested that dystrophin and the glycoprotein complex are synthesized separately, both temporally and spatially, and only become associated at the plasma membrane during the later stages of regeneration. The expression of beta-dystroglycan in the regenerating muscle fibers was first seen at sites of newly forming plasma membrane that were closely associated with the old basal lamina tube. The basal lamina may therefore have a regulatory or modulatory role in the expression of the DAG.
Vater
R
R
Muscular Dystrophy Group Research Laboratories, Newcastle General Hospital, Newcastle upon Tyne, United Kingdom.
Harris
J B
JB
Anderson
V B
VB
Roberds
S L
SL
Campbell
K P
KP
Cullen
M J
MJ
D000818:Animals; D000911:Antibodies, Monoclonal / Q000276:immunology; D001485:Basement Membrane / Q000187:drug effects; D015153:Blotting, Western; D003598:Cytoskeletal Proteins / Q000096:biosynthesis* / Q000235:genetics; D049030:Dystroglycans; D016189:Dystrophin / Q000378:metabolism*; D004546:Elapid Venoms / Q000633:toxicity; D005260:Female; D005455:Fluorescent Antibody Technique; D015870:Gene Expression; D008562:Membrane Glycoproteins / Q000096:biosynthesis* / Q000235:genetics; D018482:Muscle, Skeletal / Q000187:drug effects / Q000473:pathology / Q000502:physiology*; D051381:Rats; D017208:Rats, Wistar; D012038:Regeneration; D049031:Sarcoglycans; D012508:Sarcolemma / Q000187:drug effects / Q000473:pathology
D000911:Antibodies, Monoclonal; D003598:Cytoskeletal Proteins; D016189:Dystrophin; D004546:Elapid Venoms; D008562:Membrane Glycoproteins; D049031:Sarcoglycans; D049030:Dystroglycans